Member Info for JimiHendrix

Genedrive Invitrio Diagnostic - Medtech innovation briefings - Expected publication date 29 March 2022

https://www.nice.org.uk/guidance/indevelopment?q=genedrive&ndt=Guidance&ndt=NICE+advice&ndt=Quality+standard

All of those above 25p in red are buys.

Just read a reply from Anna (via Jamie Hayes) about the DOD budget estimate for 2022. She says Genedrive haven't received any news from DOD since last year and that a positive outcome is unlikely.

That would have been a nice bonus on top of everything else we're expecting.

Many were buys showing as red.

Possibly a director buy. Might see a TR1.

Yes nice indeed. They plan to award the contract this month with delivery in June. So we could be in for a very exciting couple of weeks with AIHL, NICE guidelines and Cov POC potential sales and CTDA approval potentially on top.

I haven’t said it’s a done deal Lloyd88. MOD have simply stated they will obtain the Genedrive system this year and have budgeted $3m for it.

I would say it’s highly likely they will, and imo a contract will most likely be signed. Reading between the lines like this and taking positions early can be far more lucrative that’s waiting until the event happens, but that’s my take on it :)

Have patience, these derampers are only trying to buy back in as cheap as they think they can possibly get away with. The shareprice will be way above current levels soon, I have no doubt.

It says... "will procure the Genedrive"

Procure = obtain

Justification: In FY22 JHBI will procure the Genedrive for DR-SKO (NGB 57, USAF 85) and the Three-9 for JBTDS (NGB 19, USMC 25). FY22 will also fund fielding and program management support.

People trying to deramp it's very frustrating haha.

Yes the whole page is about Genedrive, it mentions it very clearly.

Thanks to TrickyMatters highlighting it on Twitter :)

GBP 100k worth of buys in the past few minutes.

Genedrive Hardware cost = $1.646m
Genedrive Package Fielding cost = $0.42m
Genedrive Support cost = $0.769m

Gross/Weapon System Cost = $2.835m

https://t.co/rnqzW9E0Jf

Exhibit P-5, Cost Analysis: PB 2022 Chemical and Biological Defense Program... See page 79

Am I correct in seeing they are budgeting approx $3m for Genedrive's system this year?

Those will be a nominal account for their private investor clients. It's not a holding they hold themselves that they can sell.

NICE said they were planning to update their guidelines on the 29th, which I'm anticipating may now be sooner. Yes the wider market will pile-in massively on any sales contract news, however the shareprice will be marked up instantly and online buying will be NT only or no quote available. So for me, taking a position before hand is more sensible.

From everything I've read and the buzz around AIHL/PALOH, it seems to me the writing is on the wall in terms of AIHL sales. They will undoubtedly come in a big way. It's not like they're trying to sell a covid test amoungst high competition or a lifestyle product. The NHS co-developed AIHL test will need to be adopted everywhere where it is beneficial.

EU sales for AIHL will be here far sooner than next year Lloyd, imo. They had been estimating that the test would get written into NICE guidelines much later in the year, in Autumn. However things are moving faster, it looks to me this could happen in the next couple of weeks.

Also, regarding Covid POC, the reason they were targeting Europe first is because of the delay the new CTDA regulations caused... it's in an interview or RNS. CTDA approval will most definitely cause a huge rise in shareprice imo, I have no doubt about that.

I can see this erupting on the NICE update, which we know will arive sometime between now and the 29th. Things are moving fast here now, it's great to see :)

They may also be trying to accumilate stock after that huge 1 million buy. Share prices often drop a little after a large buy before heading up again. I'm certainly not going to to risk trading mine with what we think the NICE guidelines will be.